Table 2.
Treatment characteristics
| All patients (n=30) | GT1 patients (n=17) | GT3 patients (n=10) | |
|---|---|---|---|
| Study perioda (days), mean ± SD | 431.8 ± 108.9 | 433.2 ± 125.1 | 420.5 ± 91.8 |
| Duration of treatment (days), average ± SD | 236.6 ± 81.9 | 230.2 ± 81.1 | 233.8 ± 85.0 |
| RVR, n (%) | 23 (76.7) | 16 (94.1) | 6 (60) |
| Treatment received, n (%) | |||
| Telaprevir, Peg-IFN, RBV | 11 (36.7) | 11 (64.7) | 0 (0) |
| Boceprevir, Peg-IFN, RBV | 4 (13.3) | 4 (23.5) | 0 (0) |
| Simeprevir, Peg-IFN, RBV | 1 (3.3) | 1 (5.9) | 0 (0) |
| Peg-IFN, RBV | 14 (46.7) | 1 (5.9) | 10 (100) |
| Patients requiring dose reductions, n (%) | 8 (26.7) | 7 (41.2) | 1 (10) |
| RBV dose reduction, n (%)b | 7 (23.3) | 6 (35.3) | 0 (0) |
| Peg-IFN dose reduction, n (%) | 3 (10) | 2 (11.8) | 1 (10) |
| Patients requiring drug cessation (temporary), n (%) | 3 (10.0) | 2 (11.8) | 1 (10) |
| Peg-IFN drug cessation (temporary), n (%) | 2 (6.7) | 1 (5.9) | 1 (10) |
| Telaprevir drug cessation (temporary), n (%) | 1 (3.3) | 1 (5.9) | 0 (0) |
| RBV drug cessation (temporary), n (%) | 1 (3.3) | 1 (5.9) | 0 (0) |
| Patients requiring drug cessation (permanent), n (%) | 2 (6.7) | 1 (5.9) | 1 (10) |
| Peg-IFN drug cessation (permanent) | 2 (6.7) | 1 (5.9) | 1 (10) |
| RBV drug cessation (permanent) | 2 (6.7) | 1 (5.9) | 1 (10) |
Notes:
a
Study period defined as from first day of treatment to clinic discharge.
b
RBV dose reduction was required for one GT6 patient.
Abbreviations: Peg-IFN, pegylated-interferon; RBV, ribavirin; RVR, rapid virological response rate (undetectable serum HCV RNA level at week 4 of treatment); SD, standard deviation.